Copyright
©The Author(s) 2017.
World J Gastroenterol. Nov 7, 2017; 23(41): 7387-7396
Published online Nov 7, 2017. doi: 10.3748/wjg.v23.i41.7387
Published online Nov 7, 2017. doi: 10.3748/wjg.v23.i41.7387
Figure 2 Dose-response effect of fecal calprotectin concentration on the probability for relapse both at 3- as well as at 6-mo post-measurement.
Cumulative number of patients with clinical relapse during 6-mo follow-up in relation to baseline concentration of fecal calprotectin. Patients belonging to the groups with higher FC values have an increased probability to relapse within both 3 and 6 mo of follow up. FC: Fecal calprotectin.
- Citation: Kostas A, Siakavellas SI, Kosmidis C, Takou A, Nikou J, Maropoulos G, Vlachogiannakos J, Papatheodoridis GV, Papaconstantinou I, Bamias G. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease. World J Gastroenterol 2017; 23(41): 7387-7396
- URL: https://www.wjgnet.com/1007-9327/full/v23/i41/7387.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i41.7387